preci
precious in precision



Primary Cell Technologies

for translational research

preci

precious in precision

Addressing the Translational Research Demands

Leveraging its extensive clinical sourcing capabilities, Preci has developed a comprehensive platform capable of generating a variety of disease models. These models are supported by detailed histological and molecular data, along with drug action profiles. Through this platform, we can offer researchers access to multiple disease models, seamlessly transferring them for their studies. Alternatively, for added convenience, Preci offers in-house drug candidate profiling and biomarker studies.

By employing advanced cell culture techniques, including spheroid, organoid, and co-culture models, we can generate multi-donor panels for testing a wide range of therapeutic modalities. Additionally, our human ECM products can be integrated into these models, enabling the creation of isogenic models that incorporate the donor's native ECM, pathology-relevant cells, and even immune cells.



Facilities

Cell culture laboratories for working with non-sterile and sterile biospecimens

High-throughput imaging and functional assays

ELISA, qPCR, flow cytometry, and tandem mass-spectrometry

Biospecimen storages at -80°C and >150°C

FFPE preparation, histology and IHC

Sequencing and bioinformatic analysis

preci

precious in precision

Projects portfolio



Liver Stellate Cells within isogenic human liver fibrosis-derived ECM hydrogels

Nosology: liver fibrosis

Timeline:

- Procedure development and validation (2 months)
- 5-donor cultures panel establishment (2 months)
- Drug action profiling (imaging-based) using reference fibrosis activators and inhibitors (<1 month)

Glioma tumoroid model establishment



Nosology: IDH-positive high-grade glioma

Timeline:

- Procedure establishment and validation (2 months)
- Collection and production of 10 donor-derived models (3 months)



Hepatocellular carcinoma models for gene therapy evaluation



Nosology: HBV/HCV-free HCC

Timeline:

- Selection of the most task-relevant model (3 months).
- Collection of 5 donors-derived cells (3 months).
- Imaging-based assay development, validation and execution (3 months)

preci

precious in precision

Rapid spheroid panels generation: microfluidic approach

A key challenge in primary cell modeling lies in reproducibility, scalability, and donor-to-donor variability. To address these obstacles, we have implemented a microfluidic spheroid generation procedure. This process produces highly homogeneous capsules, each containing a precisely defined number of cells. Within the confined environment, cell spheroids spontaneously form within 2 to 12 hours, further reinforced by hydrogel formation within the capsule. The resulting droplets are then separated from oil and plated on plastic. This procedure enables the generation of over 5,000 microspheres per hour, allowing the creation of a homogeneous array from a single tumor.



This advanced cell culture technique is offered as part of Preci's in-house capabilities for cell model establishment and therapeutic profiling. Various cell types, including immune cells, can be integrated during the model generation phase and utilized throughout the assay process.

Contact us: hi@preci.care